en · de · es · fr · pt
sr9009-notes.peptides6155.com › Data › Mechanism And Preclinical Findings — Research Overview

Mechanism And Preclinical Findings — Research Overview

By Editorial Desk · published 2026-06-09 · last reviewed 2026-07-29 · Data

research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Related pages on this site

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

Further detail

CTC has also been applied to the staining of unmelted sections of sea ice sampled during spring and summer, which were subsequently returned to the ice core holes they were collected from for in situ incubation. After recollection, metabolic activity was halted by adding a fixative into the melting sea ice. DAPI and Alcian Blue were then used to stain subsamples of the resulting melted sea ice sample, bypassing the restrictive temperature requirement. It was found that gel-like particles of EPS associated with bacteria were in situ bacterial activity hotspots. Extracellular enzyme activity has been detected down to as low as –18 °C in unmelted sea ice using a fluorescently-labeled protein substrate analogue. Relying on melted sea ice samples runs the risk of underestimating in situ activity due to the dilution of microbial populations.

These included the fast-food Mexican eatery Taco Kid; hamburger restaurant Next Door; steakhouse Flaming Steer; and barbecue restaurant Sutphen's. All four ventures were unsuccessful and closed by the end of the decade. PepsiCo acquired Pizza Hut in November 1977. The company had over 4,000 locations by this point. In August 1994, Pizza Hut and the Santa Cruz Operation (SCO) announced PizzaNet, a pilot program in the Santa Cruz area that allowed consumers to use their own computer to order pizza delivery from a local Pizza Hut restaurant, with connection being made over the Internet to a central Pizza Hut server in Wichita, Kansas. The PizzaNet application software was developed by SCO's Professional Services group. PizzaNet was based on the first commercially licensed and bundled Internet operating system, SCO Global Access. On May 30, 1997, PepsiCo spun off Pizza Hut, along with Taco Bell and Kentucky Fried Chicken, into a new company named Tricon Global Restaurants, Inc. The company assumed the name of Yum! Brands on May 22, 2002. On March 31, 2011, Priszm, the largest franchisee for Pizza Hut restaurants in Canada at the time, went into bankruptcy protection in Ontario and British Columbia. In 2015, the oldest continuously operating Pizza Hut, which was the restaurant located in the Aggieville District of Manhattan, Kansas, closed after having opened as the 8th location in 1960. The company announced a rebrand that began on November 19, 2014, in an effort to increase sales, which had dropped in the previous two years.

==== Alternative ==== Oil-fired steam turbines powered the British K-class submarines, built during World War I and later, to give them the surface speed to keep up with the battle fleet. The K-class subs were not very successful, however. Toward the end of the 20th century, some submarines—such as the British Vanguard class—began to be fitted with pump-jet propulsors instead of propellers. Though these are heavier, more expensive, and less efficient than a propeller, they are significantly quieter, providing an important tactical advantage.

Sources: en.wikipedia.org

Background from the literature

== External links == Nonlinear Fracture Mechanics Notes by Prof. John Hutchinson, Harvard University Notes on Fracture of Thin Films and Multilayers by Prof. John Hutchinson, Harvard University Fracture Mechanics by Piet Schreurs, TU Eindhoven, The Netherlands

=== Other interventions === A 2024 review found that fecal microbiota transplantation may reduce pain intensity and improve fatigue and quality of life in patients with fibromyalgia, but evidence was insufficient at that stage to support use. Research on gut microbiome links with FM continues. Hyperbaric oxygen therapy (HBOT) has shown beneficial effects in treating chronic pain by reducing inflammation and oxidative stress. However, treating fibromyalgia with hyperbaric oxygen therapy is still controversial, in light of the scarcity of large-scale clinical trials. In addition, hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it. An evaluation of nine trials with 288 patients in total found that HBOT was more effective at relieving fibromyalgia patients' pain than the control intervention. In most of the trials, HBOT improved sleep disturbance, multidimensional function, patient satisfaction, and tender spots. Negative outcomes (predominantly mild barotrauma (air pressure effect on ear or lung) that could be resolved spontaneously) were experienced by 24% of the patients, but they were not prevented from completing the treatment regimen, and no serious side effects, complications, or deaths were reported.

== Diagnosis == The symptoms of a metabolic myopathy can be easily confused with the symptoms of another disease. As genetic sequencing research progresses, a non-invasive neuromuscular panel DNA test can help make a diagnosis. Whole genome sequencing is required in more complex cases. If the DNA test is inconclusive (negative or VUS), then a muscle biopsy is necessary for an accurate diagnosis. In mitochondrial myopathies involving a single mtDNA deletion, DNA would have to be tested from affected muscle tissue rather than saliva or blood as unaffected tissues would show normal or near normal levels of mtDNA. A blood test for creatine kinase (CK) can be done under normal circumstances to test for signs of tissue breakdown, or with an added cardio portion that can indicate if muscle breakdown is occurring. In metabolic myopathies, baseline CK is either normal or elevated. An electromyography (EMG) test is sometimes taken in order to rule out other disorders if the cause of fatigue is unknown. In metabolic myopathies, the EMG is either normal or myopathic, but spontaneous activity is usually absent. An exercise stress test can be used to determine an inappropriate rapid heart rate (sinus tachycardia) response to exercise, which is seen in GSD-V, other glycogenoses, and mitochondrial myopathies. A 12 Minutes Walk Test (12MWT) can also be used to determine "second wind" which is also seen in McArdle disease (GSD-V) and phosphoglucomutase deficiency (PGM1-CDG/CDG1T/GSD-XIV).

Sources: en.wikipedia.org

Further detail

== Self-resistance == Tabtoxin resistance protein (TTR) is an enzyme that catalyzes the acetylation of TBL, rendering tabtoxin-producing pathogens tolerant to their own phytotoxins. The structure of an inactivated mutant of TTR is solved with its natural cofactor acetyl-CoA to 1.55 Å resolution. The binary complex forms a characteristic V-shape for substrate binding and contains the four motifs conserved in the GCN5-related N-acetyltransferase (GNAT) superfamily, which also includes the histone acetyltransferases (HATs). There are reports that TTR possesses HAT activity and suggest an evolutionary relationship between TTR and other GNAT members. The production of tabtoxin itself is also part of the self-resistance strategy. These pathogens produce TBL before tabtoxin is produced; to detoxify, the enzyme TblF links TBL to threonine (Thr), producing a non-toxic product.

Staley met guitarist Jerry Cantrell at a party in Seattle while working at Music Bank rehearsal studios in 1987. A few months before that, Cantrell had watched Staley performing with his then-band, Alice N' Chains, in his hometown at the Tacoma Little Theatre, and was impressed by his voice. Cantrell was homeless after being kicked out of his family's house, so Staley invited Cantrell to live with him at the Music Bank. The two fast friends lived as roommates for over a year in the dilapidated rehearsal space they shared. Alice N' Chains soon disbanded and Staley joined a funk band, which at the time also required a guitarist. He asked Cantrell to join as a sideman. Cantrell agreed on condition that Staley join his band, which at the time did not have a name and included drummer Sean Kinney and bassist Mike Starr. They started auditioning terrible lead singers in front of Staley to send a hint, which made him angry. The final straw for Staley was when they auditioned a male stripper in front of him – he decided to join the band after that. Cantrell said this about Staley's voice: "I knew that voice was the guy I wanted to be playing with. It sounded like it came out of a 350-pound biker rather than skinny little Layne. I considered his voice to be my voice." Eventually the funk project broke up, and in 1987, Staley joined Cantrell's band on a full-time basis. The band had names like "Fuck" and "Diamond Lie", the latter being the name of Cantrell's previous band.

During the 1990s, people in the West were also interested in the radioactive hazards of nuclear facilities, decommissioned nuclear submarines, and the processing of nuclear waste or spent nuclear fuel. It was also known in the early 1990s that the USSR had transported radioactive material to the Barents Sea and Kara Sea, which was later confirmed by the Russian parliament. The crash of the K-141 Kursk submarine in 2000 in the west further raised concerns. In the past, there were accidents involving submarines K-19, K-8, a K-129, K-27, K-219 and K-278 Komsomolets.

Defects of spectrin, ankyrin (most commonly), or PROTEIN 4.2 lead to reduced structural integrity of the plasma membrane, destabilizing the overlying lipid bilayer, and releasing band 3-containing microvesicles. Band-3 is important for gas exchange (as seen above). Defects of band 3 lead to band 3 deficiency and loss of its lipid-stabilizing effect within the plasma membrane lipid bilayer. This results in the release of band 3-free microvesicles. Both pathways result in compromised plasma membrane integrity, decreased surface area, and formation of spherocytes with decreased mechanical compliance during circulation.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

How should SR9009 be stored?

Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.

Network